1Q26 Update. IND Clearance Expected Soon in Q2. More Data Later in September for Longer Dosing in P1b Trial. Reinforcement of Prior Trends Would Be Impressive.

Research evidence excerpt

1Q26 Update. IND Clearance Expected Soon in Q2. More Data Later in September for Longer Dosing in P1b Trial. Reinforcement of Prior Trends Would Be Impressive.

t investments in securities may pose significant risks due to the inherent uncertainty

associated with relying on forecasts of various factors that can affect the earnings, cash flow and overall valuation of a company.

Any investment in securities should be undertaken only upon consideration of issues relating to the recipient’s overall investment

portfolio and objectives (such as diversification by asset class, industry or company) as well as time horizon and liquidity needs.

Further, past performance should not be taken as an indication or guarantee of future performance, and no representation or

warranty, express or implied, is made regarding future performance. There may be time limitations on the exercise of options

or other rights in any securities transactions.

Investing in foreign markets and securities, including ADRs, is subject to additional risks such as currency fluctuation, limited

information, political instability, economic risk, and the potential for illiquid markets. Investing in emerging markets may

accentuate these risks. Non-U.S. reporting issuers of foreign securities, however, may not make regular or complete public

disclosure relating to their financial condition or the securities that they issue.

The trademarks and service marks contained herein are the property of their respective owners. Third-party data providers make

no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and

shall not have liability of any damages of any kind relating to such data. The report or any portion hereof may not be reprinted,